LWLaura Willing

Laura Willing

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laura Willing has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Civic Engagement for a Healthier Tomorrow: Lessons Learned from a Voter Registration Campaign in a Large Pediatric Healthcare System

    by Tyler Rapp, Laura Willing, Danielle Dooley, Elizabeth Ireson, Desiree de la Torre, Amanda Stewart

    Health outcomes and voting are inextricably linked, making healthcare spaces growing sites of opportunity for voter registration efforts. This case study of a comprehensive, nonpartisan voter registration effort at Children’s National, a large freestanding children’s hospital in Washington, D.C. and at its network of outpatient centers across D.C., Maryland, and Virginia, highlights why advocacy focused on voting is essential to health and healthcare. Using materials from Vot-ER and customized materials including physical flyers and voting guides incorporated into the electronic health record, our efforts resulted in the engagement of hundreds of eligible voters in inpatient and outpatient settings that can be used as a model by other healthcare systems. Lessons learned include the importance of collaborating with hospital leadership, starting efforts early, identifying voter registration champions, and understanding voting policies and regulations, especially in institutions serving patients and families from multiple voting jurisdictions. Our team advocates for more healthcare systems to participate in voter registration and mobilization efforts and support staff, patients, and families in voting. Our efforts to advocate for increased voter registration efforts within our healthcare system are aligned with our focus on child health, as we recognize that voter participation helps shape the policies and public investments that influence child and family health outcomes. Other advocates can adapt this model as a scalable framework for implementing voter registration initiatives across diverse healthcare systems and voting jurisdictions.

  • Open Access

    Prescribing Nasal Naloxone in Pediatrics: A Clinical Perspective on Reducing Overdose Deaths

    by Sivabalaji Kaliamurthy, Jesse Ross, Laura Willing

    Adolescents continue to be at increased risk for fatal opioid overdoses, driven by the widespread presence of illicitly manufactured fentanyl. Naloxone, a lifesaving opioid antagonist and an effective overdose reversal agent, remains underutilized in pediatric and adolescent populations. This clinical perspective addresses gaps in naloxone accessibility, common barriers that prevent clinicians from prescribing it, and solutions to overcome these barriers by presenting and discussing a case study of a 16-year-old girl suspended for carrying nasal naloxone to school. Our objectives are to (1) outline clinical recommendations for identifying at-risk adolescents who should be prescribed naloxone, emphasizing its utility for adolescents using opioids or other substances and those with social connections to individuals engaging in substance use; (2) review common school policies that place naloxone in nurses’ stations and the impracticality of retrieving it in emergencies; and (3) provide evidence debunking the myth that naloxone access encourages substance use and propose advocacy strategies for clinicians to navigate restrictive school policies and community stigma. This clinical perspective also touches on the ethical considerations surrounding adolescent confidentiality laws, which may limit naloxone prescribing in cases where parental consent is unattainable. Several actionable solutions are discussed, including prescribing naloxone universally with comprehensive education on its benefits and safety profile. By equipping clinicians with evidence-based strategies and advocacy tools, this article aims to enhance the accessibility of naloxone for adolescents, reducing the tragic toll of opioid overdoses.


  • A pilot study of group Exposure Response Prevention for Pediatric Obsessive-Compulsive Disorder: In-Person and Virtual Delivery with Caregiver Involvement

    by Lilia Mucka Andrew, Irene Zhang, Nicholas Lohman, Laura Willing, Perrine Heymann, Tiffany Kichline, Sanchita Sharma, Mi-Young Ryee

  • Treatment Approaches and Growth Parameters in Pediatric ADHD: Examining Differences Across Race

    by Ayman Saleh, Laura Willing, Mi-Young Ryee, Kirsten Russo, Waverly Gestrich-Thompson, Lilia Mucka Andrew

    Racial disparities in diagnosis and treatment of pediatric mental health conditions are well-documented. Stimulants are the cornerstone of ADHD treatment, but long-term effects on growth remain a concern. We retrospectively analyzed treatment history (e.g., duration, medication, comorbidity), growth, and demographics (e.g., socioeconomic status and race) from 197 pediatric patients with ADHD. We found Black and Hispanic patients were younger, had lower socioeconomic status, and were followed for longer than White patients. Despite similar amounts of comorbidities across racial groups, White patients received more antidepressants (p < 0.001). Stimulant users were prescribed fewer atomoxetine, antidepressant, and antipsychotic medications but had longer follow-up and more total medications. We saw a significant decrease in height Z-scores for the whole cohort, and an increase in BMI Z-scores in Hispanic patients. The findings highlight disparities in pharmacological treatment of pediatric patients with ADHD and more research is needed to understand factors contributing to potential biases to reduce inequities in care and improve patient outcomes.

  • Advocacy Education in Child and Adolescent Psychiatry: Results of a National Survey of Child and Adolescent Psychiatry Fellowship Programs

    by Laura Willing, Ellen Goldman

    Objective Advocacy education is an important competency in physician education. The medical education literature includes several examples of advocacy curricula in graduate medical education programs, but few in child and adolescent psychiatry fellowship programs. The authors describe a survey they conducted on the state of advocacy education in child and adolescent psychiatry fellowship programs. Methods In October 2024, the authors sent a survey to child and adolescent psychiatry fellowship program directors. The web-based survey asked questions regarding the purpose of the curriculum/advocacy experience, learning objectives, types of content, teaching formats, faculty, assessment of learning, and facilitators and barriers to the curriculum/learning experiences. Results Of the 33 child and adolescent psychiatry fellowship directors who responded to the survey, 27 (82% of respondents) indicated having advocacy experiences or curricula. The most common purposes of the advocacy experiences were to “gain awareness of child mental health systems-level issues,” “learn about health policy/health laws and regulations,” “gain confidence and learn advocacy skills,” and “learn how to influence policy.” The most common types of educational content in the advocacy experience/curriculum were “legislative advocacy skills” and “social determinants of health/health equity.” Conclusions The majority of respondents indicated having advocacy education in their child and adolescent psychiatry fellowship programs. The survey sheds light on common purposes of this training, types of educational content, teaching formats, and common barriers and facilitators to advocacy education in child and adolescent psychiatry fellowship programs.

  • Open Access

    So, you want to be a health policy scholar - Now what? Challenges and opportunities related to mentorship, academic support, and institutional environments in health policy scholarship

    by Emily R. Miller, Matthew Magyar, Laura Willing, Elizabeth Barnert, Lois Lee

    Health policy research is foundational to advocacy within the academy of medicine and benefits from experienced mentors, research support, and institutional prioritization. In this insight article, the authors describe experiences with and propose solutions to unique barriers to health policy scholarship and related physician advocacy.


  • DC Mental Health Access in Pediatrics: Evaluating a Child Psychiatry Access Program in Washington, DC

    by Leandra Godoy, Samantha Hamburger, Lindsay R. Druskin, Laura Willing, Jeffery Q. Bostic, Sean D. Pustilnik, Lee S. Beers, Matthew G. Biel, Melissa Long


  • Open Access

    Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial

    by James C. Garbutt, Alexei B. Kampov-Polevoy, Cort Pedersen, Melissa Stansbury, Robyn Jordan, Laura Willing, Robert J. Gallop

    Identification of new medications for alcohol use disorder (AUD) is important for improving treatment options. Baclofen, a GABABagonist, has been identified as a potential pharmacotherapy for AUD. In a 16-week double-blind, randomized, placebo-controlled trial, we investigated 30 and 90 mg/day of baclofen compared to placebo and examined effects of dose, sex, and level of pretreatment drinking. One hundred and twenty participants with DSM-IV alcohol dependence (age 46.1 (sd = 10.1) years, 51.7% male) were randomized after exclusion for unstable medical/psychiatric illness and/or dependence on drugs other than nicotine. Seventy-three participants completed the trial. A main effect of baclofen was found [%HDD (F(2,112) = 4.16,p = 0.018,d = 0.51 95%CI (0.06–0.95), 13.6 fewer HDD) and %ABST (F(2,112) = 3.68,p = 0.028,d = 0.49 95%CI (0.04–0.93), 12.9 more abstinent days)] and was driven by the 90 mg/day dose. A sex × dose interaction effect was present for both %HDD (F(2,110) = 5.48,p = 0.005) and %ABST (F(2,110) = 3.19,p = 0.045). Men showed a marginally positive effect for 90 mg/day compared to PBO (%HDD t(110) = 1.88,p = 0.063,d = 0.36 95%CI (−0.09–0.80), 15.8 fewer HDD days; %ABST t(110) = 1.68 (p = 0.096,d = 0.32 95%CI (−0.12–0.76), 15.7 more ABST)) with no effect for 30 mg/day. Women showed a positive effect for 30 mg/day (%HDD, t(110) = 3.19,p = 0.002,d = 0.61 95%CI (0.16–1.05), 26.3 fewer HDD days; %ABST t(110) = 2.73,p = 0.007,d = 0.52 95%CI (0.07–0.96), 25.4 more ABST days) with marginal effects for 90 mg/day on %ABST (p = 0.06) with drop-outs/dose reduction from sedative side-effects of 59% in women at 90 mg/day compared to 5% for men. These findings support the hypothesis that baclofen has efficacy in AUD and suggest that dose and sex be further explored as potential moderators of baclofen response and tolerability.